Skip to product information
1 of 1

WALA remedies GmbH

ISCUCIN crataegi Strength A Ampoules

ISCUCIN crataegi Strength A Ampoules

Regular price £196.35 GBP
Regular price £300.00 GBP Sale price £196.35 GBP
Sale Sold out
Taxes included.

ISCUCIN crataegi Strength A Ampoules

Pack size:10 x 1 ml Dosage form:Ampoules

Iscucin Crataegi Strength A, liquid dilution for injection. Active ingredient: Viscum album (Crataegi) e planta tota K. Indications: Registered homeopathic medicinal product of the anthroposophical therapeutic approach, therefore no therapeutic indication is specified.

For risks and side effects, read the package insert and ask your doctor or pharmacist.


PACKAGE LEAFLET: INFORMATION FOR THE USER

Iscucin Crataegi Strength A, liquid dilution for injection
Active ingredient: Viscum album (Crataegi) e planta tota K

Composition:
1 ampoule contains: Viscum album (Crataegi) e planta tota K Dil. Strength A 1 ml (HAB, Vs. 38). Other ingredients: Sodium chloride, sodium bicarbonate, water for injections.

Indications:
Registered homeopathic medicinal product of the anthroposophical therapeutic approach, therefore without a specified therapeutic indication.

Contraindications:
Iscucin Crataegi should not be used in the following cases:

  • known allergy to mistletoe preparations.
  • acute inflammatory or high fever diseases, treatment should be interrupted until the signs of inflammation subside.
  • Hyperthyroidism with unbalanced metabolism.



Precautions for use and warnings:
Consult a doctor before using this medicine.

What should you bear in mind if you are pregnant or breastfeeding?
The effects of this medicine on pregnancy, the development of the unborn child, childbirth, and the development of the child after birth, particularly on the development of blood cells and the immune system in the unborn child/infant, have not been studied. The potential risk to humans is therefore unknown. Caution is advised when used during pregnancy and while breastfeeding. Consult your doctor before using this medicine. It is expressly recommended that you increase the dosage carefully. An excessive increase in the dose, particularly if you skip a dilution level in the lower potencies (e.g., from strength C to strength E), may cause allergic reactions.

Dosage and method of administration:
As directed by your doctor. To avoid hypersensitivity reactions, the dosage must be increased gradually. Start with strength A. When increasing the dose carefully up to once daily use and switching to the next higher strength, the local inflammatory reaction at the injection site should not exceed a diameter of 5 cm each time. Skipping a dilution level in the lower potencies (e.g. from strength C to strength E) may result in allergic reactions requiring emergency measures.

Duration of use:
Treatment of an illness should be completed after 2 weeks. If no improvement occurs within this period, a doctor should be consulted. The duration of treatment for chronic illnesses requires consultation with a doctor.

Side effects:
What side effects can occur when using Iscucin Crataegi?
Like all medicines, Iscucin Crataegi can cause side effects, although not everybody experiences them. A slight increase in body temperature, localized inflammatory reactions around the subcutaneous injection site, and temporary slight swelling of regional lymph nodes are harmless. In case of intolerance to mistletoe, local or general allergic or allergy-like reactions such as generalized itching, hives, rash, facial swelling (Quincke's edema), chills, shortness of breath, or shock may occur, requiring discontinuation of the product and immediate medical attention. No information on frequency is available.

Contents:
10 x 1 ml.

Pharmaceutical Entrepreneur and Manufacturer:
WALA Heilmittel GmbH
Dorfstraße 1,
73087 Bad Boll/Eckwälden.

This leaflet was last revised in January 2025.

Source: Information from the Wala catalogue
as of: 04/2025

Active ingredient: Viscum album (Crataegi) e planta tota K. Indications: Registered homeopathic medicinal product of the anthroposophical therapeutic approach, therefore without specification of a therapeutic indication.

View full details